Jörg Täubel

4.9k total citations · 4 hit papers
86 papers, 2.0k citations indexed

About

Jörg Täubel is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Physiology. According to data from OpenAlex, Jörg Täubel has authored 86 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Cardiology and Cardiovascular Medicine, 29 papers in Molecular Biology and 11 papers in Physiology. Recurrent topics in Jörg Täubel's work include Cardiac electrophysiology and arrhythmias (32 papers), Receptor Mechanisms and Signaling (11 papers) and Statistical Methods in Clinical Trials (9 papers). Jörg Täubel is often cited by papers focused on Cardiac electrophysiology and arrhythmias (32 papers), Receptor Mechanisms and Signaling (11 papers) and Statistical Methods in Clinical Trials (9 papers). Jörg Täubel collaborates with scholars based in United Kingdom, United States and Japan. Jörg Täubel's co-authors include Ulrike Lorch, Georg Ferber, Anna Borodovsky, Akshay Vaishnaw, Jay D. Horton, Kevin Fitzgerald, Valerie A. Clausen, David Kallend, Brian R. Bettencourt and Peter Wijngaard and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Jörg Täubel

82 papers receiving 2.0k citations

Hit Papers

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 2016 2026 2019 2022 2016 2020 2023 2024 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
    2016 586 citations Jörg Täubel et al. profile →
  2. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study
    2020 266 citations Jörg Täubel, Wilfried Hauke et al. European Heart Journal profile →
  3. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
    2023 149 citations Jörg Täubel et al. profile →
  4. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
    2024 41 citations Scott D. Solomon, Jörg Täubel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jörg Täubel United Kingdom 18 808 588 569 306 177 86 2.0k
Tsuyoshi Kobayashi Japan 30 587 0.7× 745 1.3× 932 1.6× 146 0.5× 348 2.0× 118 2.6k
Toshiyuki Kita Japan 24 624 0.8× 210 0.4× 575 1.0× 227 0.7× 49 0.3× 127 2.1k
Arash Haghikia Germany 21 682 0.8× 368 0.6× 267 0.5× 196 0.6× 26 0.1× 57 1.6k
Mark K. Wedel United States 19 434 0.5× 208 0.4× 537 0.9× 199 0.7× 43 0.2× 30 1.6k
Thomas Gautier France 29 616 0.8× 287 0.5× 966 1.7× 207 0.7× 30 0.2× 94 2.1k
Xiao‐Mei Li China 25 446 0.6× 629 1.1× 485 0.9× 199 0.7× 24 0.1× 165 2.0k
Bryan J. Barratt United Kingdom 23 826 1.0× 743 1.3× 754 1.3× 155 0.5× 16 0.1× 35 3.0k
J.H.M. Levels Netherlands 21 853 1.1× 394 0.7× 587 1.0× 206 0.7× 39 0.2× 35 2.1k
Nirmal Parajuli Canada 25 791 1.0× 754 1.3× 352 0.6× 139 0.5× 16 0.1× 44 2.1k
Matthijs Moerland Netherlands 26 567 0.7× 222 0.4× 382 0.7× 153 0.5× 13 0.1× 111 1.9k

Countries citing papers authored by Jörg Täubel

Since Specialization
Citations

This map shows the geographic impact of Jörg Täubel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörg Täubel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörg Täubel more than expected).

Fields of papers citing papers by Jörg Täubel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörg Täubel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörg Täubel. The network helps show where Jörg Täubel may publish in the future.

Co-authorship network of co-authors of Jörg Täubel

This figure shows the co-authorship network connecting the top 25 collaborators of Jörg Täubel. A scholar is included among the top collaborators of Jörg Täubel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörg Täubel. Jörg Täubel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goncalves, Maria B., Yue Wu, Earl E. Clarke, et al.. (2024). C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair. Frontiers in Molecular Neuroscience. 17. 1411384–1411384.
2.
Täubel, Jörg, et al.. (2023). The Reliability of Auto-Injectors in Clinical Use: A Systematic Review. Cureus. 15(7). e41601–e41601. 4 indexed citations
3.
Goncalves, Maria B., Tim Mant, Jörg Täubel, et al.. (2023). Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants. British Journal of Clinical Pharmacology. 89(12). 3573–3583. 4 indexed citations
4.
Täubel, Jörg, et al.. (2022). Effect of hyperglycaemia in combination with moxifloxacin on cardiac repolarization in male and female patients with type I diabetes. Clinical Research in Cardiology. 111(10). 1147–1160. 7 indexed citations
5.
Täubel, Jörg, et al.. (2021). Concentration‐QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers. British Journal of Clinical Pharmacology. 88(1). 128–137. 4 indexed citations
6.
7.
Täubel, Jörg, Wilfried Hauke, Steffen Rump, et al.. (2020). Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. European Heart Journal. 42(2). 178–188. 266 indexed citations breakdown →
8.
Albayaty, Muna, James Bush, Joseph Cheriyan, et al.. (2020). The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. Frontiers in Pharmacology. 11. 580560–580560.
9.
Reijntjes, Susan, Muna Albayaty, James Bush, et al.. (2018). The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. Frontiers in Pharmacology. 9. 1301–1301. 1 indexed citations
10.
Täubel, Jörg, et al.. (2018). Practical risk management in early phase clinical trials. European Journal of Clinical Pharmacology. 75(4). 483–496. 6 indexed citations
11.
Sakurai, Yuuichi, Akira Nishimura, Mark G. Hibberd, et al.. (2015). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. Clinical and Translational Gastroenterology. 6(6). e94–e94. 141 indexed citations
12.
13.
14.
Wang, Duolao, et al.. (2011). Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers. The Journal of Clinical Pharmacology. 52(9). 1441–1447. 30 indexed citations
15.
Täubel, Jörg, et al.. (2011). Shortening of the QT Interval After Food Can Be Used to Demonstrate Assay Sensitivity in Thorough QT Studies. The Journal of Clinical Pharmacology. 52(10). 1558–1565. 48 indexed citations
16.
Lorch, Ulrike, et al.. (2011). The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings. European Journal of Clinical Pharmacology. 68(5). 543–551. 10 indexed citations
17.
Dixon, Ruth, Sarah A. Job, Ruth Oliver, et al.. (2008). Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. British Journal of Clinical Pharmacology. 66(3). 396–404. 82 indexed citations
18.
Täubel, Jörg, et al.. (2001). A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24‐h intragastric pH. Alimentary Pharmacology & Therapeutics. 15(11). 1807–1817. 19 indexed citations
19.
Freston, James W., et al.. (2001). Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. The American Journal of Gastroenterology. 96(7). 2058–2065. 35 indexed citations
20.
Brown, Gail L., et al.. (2000). Phase 1 dose optimization study for V-echinocandin. 40. 371. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tsuyoshi Kobayashi Breakdown of academic impact, for papers by Toshiyuki Kita Breakdown of academic impact, for papers by Arash Haghikia Breakdown of academic impact, for papers by Mark K. Wedel Breakdown of academic impact, for papers by Thomas Gautier Breakdown of academic impact, for papers by Xiao‐Mei Li Breakdown of academic impact, for papers by Bryan J. Barratt Breakdown of academic impact, for papers by J.H.M. Levels Breakdown of academic impact, for papers by Nirmal Parajuli Breakdown of academic impact, for papers by Matthijs Moerland
Rankless by CCL
2026